U.S. Patent No. 7,407,940
Helix BioMedix, Inc., a Bothell, WA maker of boactive peptides, has been awarded a patent that covers a family of hexapeptide antimicrobial agents, including HB1345, for use as broad spectrum topical anti-infectives. HB1345 will be developed initially for dermatological indications such acne, rosacea and atopic dermatitis. Subsequent clinical applications are anticipated to include prevention of hospital acquired infections, such as those caused by MRSA and other multi-resistant pathogens.